Plenolin
Plenolin is an anticancer agent. Plenolin exhibits inhibitory activity against human epidermoid carcinoma cells. Plenolin shows in vivo antitumor activity against ascites carcinosarcoma and lymphocytic leukemia in rodent models. Plenolin can be used for research related to ascites tumors and leukemia.
For research use only. We do not sell to patients.
- CAS No.: 34257-95-9
- Formula: C15H20O4
- Molecular Weight:264.32
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEp-2 | ED50 |
0.81 μg/mL
Compound: 12
|
Cytotoxicity against human Hep2 cells assessed as growth inhibition by microtiter method
Cytotoxicity against human Hep2 cells assessed as growth inhibition by microtiter method
|
[PMID: 671468] |
| HEp-2 | ED50 |
0.814 μg/mL
Compound: 3
|
Cytotoxicity against human Hep2 cells
Cytotoxicity against human Hep2 cells
|
[PMID: 845864] |
| HepG2 | ED50 |
0.8 μg/mL
Compound: 6
|
Cytotoxicity against human HepG2 cells
Cytotoxicity against human HepG2 cells
|
[PMID: 20187635] |
In Vitro
In Vivo
For male rats bearing Walker 256 ascitic carcinosarcoma, the T/C value of mean survival days is 207 when treated with Plenolin at 2.5 mg/kg via i.p. administration[1].
Plenolin (25 mg/kg; i.p.) results in a T/C value of 134 for mean survival days in male DBA/2 mice inoculated with P388 leukemia[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CF1 (male, ~30 g, implanted with 106 Ehrlich ascites carcinoma cells)[1]
-
Dosage:33.3 mg/kg/day
-
Administration:i.p.; daily
-
Result:Achieved 100.0% inhibition of tumor growth.
Reduced ascites-crit to 0.
Reduced total ascites fluid volume to 0.0 mL.
Ensured 100% survival of 5 treated mice to day 7.
Chemical Information
-
CAS No. 34257-95-9
-
Molecular Weight 264.32
-
Formula C15H20O4
-
SMILES
C[C@@]12[C@]([C@H](C)C[C@@]3([C@]([C@@H]1O)([C@H](C)C(=O)O3)[H])[H])(C=CC2=O)[H]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Plenolin Related Classifications
HY-165375 Related Classifications
Powered by Bioz